NorthStar Medical Radioisotopes and Convergent Therapeutics have inked a contract for manufacturing services, collaborating on CONV01-α, targeted radiotherapy for prostate cancer.
CONV01-α, spearheaded by Convergent, employs a monoclonal antibody linked to the radionuclide Ac-225, targeting the PSMA receptor prevalent in prostate cancer cells. Upon regulatory approval, NorthStar’s expertise will encompass manufacturing, quality control, and potential commercial production of CONV01-α.
This partnership underscores the growing significance of radiotherapy, particularly Ac-225-based therapies, in combating various diseases. NorthStar aims to expedite the development and delivery of innovative radiopharmaceuticals, such as CONV01-α, to meet the unmet medical needs of patients.
The manufacturing agreement will facilitate Phase 2 clinical trials of CONV01-α and potentially its commercial production, enabling Convergent to broaden its clinical development program and explore combination therapies.
CONV01-α harnesses the precision of antibodies with the potency of alpha-emitting radionuclides, delivering targeted radiotherapy to prostate cancer cells. Its unique combination sets it apart from other PSMA-targeted therapies. The alpha particles emitted by Ac-225 directly attack cancer cells, inducing DNA damage and cell death.
Convergent’s upcoming Phase 2 clinical trial aims to build upon the foundation laid by earlier clinical data. The company anticipates swiftly advancing to Phase 3 trials to accelerate the development of CONV01-α as a promising treatment for prostate cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
